Press Releases

Nymox Announces Expanded Marketing Plans

July 2, 2018:

Nymox Pharmaceutical Corporation announced today that following the recently announced increased manufacturing capabilities, the Company has formally decided to expand its European marketing plans for Fexapotide Triflutate (FT) to all countries in the European Community.


NYMOX Successfully Achieves Manufacturing Scale-Up

June 7, 2018:

Nymox Pharmaceutical Corporation is pleased to report that manufacturing scale-up milestones have been reached for the Company’s lead compound Fexapotide Triflutate (FT).


Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco

May 22, 2018:

Nymox Pharmaceutical Corporation is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend.


Nymox’s Fexapotide Featured in Broadcast of Grand Rounds in Urology

May 11, 2018:

Nymox Pharmaceutical Corporation is pleased to announce that an informative interview and presentation was released on Grand Rounds in Urology, a highly respected and authoritative urologic professional community, and host of international conferences and symposia that bring together the top thought leaders in the treatment of urologic disease, with meetings that focus on current best treatment practices as well as future trends and directions.


Nymox Announces Relocation of Company Headquarters to Switzerland

May 7, 2018:

Nymox Pharmaceutical Corporation is pleased to announce that it has initiated the process of relocating the Company Headquarters from Nassau, Bahamas to Zug in Switzerland.


Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco ‎May 20

May 2, 2018:

Nymox Pharmaceutical Corporation is pleased to announce that there will be a Symposium on the Company’s lead drug Fexapotide held at the Annual Meeting of the American Urological Association on May 20 in San Francisco.


Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors

April 12, 2018:

Nymox Pharmaceutical Corporation is pleased to announce today that the Company has successfully secured $16.25 million in new equity capital with several professional high net worth investors.


New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology

April 10, 2018:

A new online published commentary about Nymox’s Fexapotide 2018 clinical trial results publication in World Journal of Urology has newly appeared today on UroToday in its “Beyond the Abstract” section, along with the abstract of the World Journal of Urology article.


Symposium and Panel Discussion on Nymox’s Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3

March 1, 2018:

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association Mid-Atlantic Section, in Amelia Island FL March 3.


Nymox Announces US NDA for Fexapotide for BPH

February 5, 2018:

Nymox Pharmaceutical Corporation announced today that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US.